Oliver Haill has been writing about companies and markets for more than a decade and a half. In recent years he has been freelancing, with contracts at the Financial Times Group, ITV, Press Association, Reuters sports desk, Gracenote Sports, Bullbearings and latterly as managing editor at the Sharecast newswire. He cut his teeth as a financial journalist at Growth Company Investor not long after the dotcom bubble burst, focusing on AIM companies and other small caps, a few years later becoming head of research.
Pharma giant had been targeting annual peak sales of $2bn for the drug, of which $400mln was from ovarian cancer
“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”
Revenues in the first year are expected to exceed £1mln and the contract offers the potential for “material increases”
Earnings growth guidance for the year to end-September has been upped to 5%-7% from the previous 4%-6% forecast
Interim analysis of a phase III clinical trial has revealed that after 12 months, 88% of people saw no progression of the disease if they were given the drug
Online grocery company acquires Europe's largest vertical farm, based in Scunthorpe, and invests in the formation of a new joint venture with US and Dutch vertical farmers
Three-year deal guarantees market exclusivity for local partner if it hits minimum sales targets
"We are now delivering on clinical milestones, with strong clinical data, and a compelling pipeline for our proprietary drug delivery platforms, all of which are now into the clinic"